¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"diffuse, mixed small and large cell lymphoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granule cell
    °ú¸³¼¼Æ÷
  • granulosa cell
    °ú¸³Ãþ¼¼Æ÷
  • granulosa cell carcinoma
    °ú¸³¼¼Æ÷¾ÏÁ¾
  • granulosa cell tumor
    °ú¸³¸·¼¼Æ÷Á¾¾ç
  • granulosa-theca cell tumor
    °ú¸³³­Æ÷¸·¼¼Æ÷Á¾¾ç
  • hypersensitized cell
    °ú¹Î°¨¼¼Æ÷
  • hypoxic cell sensitizer
    Àú»ê¼Ò¼¼Æ÷¹Î°¨Á¦
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷
  • HeLa cell
    Çï¶ó¼¼Æ÷
  • hair cell
    Åм¼Æ÷
  • helmet cell
    Åõ±¸¼¼Æ÷
  • helper cell
    µµ¿ò¼¼Æ÷, Á¶·Â¼¼Æ÷
  • helper cell activity
    µµ¿ò¼¼Æ÷Ȱ¼º
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä, Ç÷±¸Çü¼º¼¼Æ÷À̽Ä
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
  • horizontal cell
    ¼öÆò¼¼Æ÷
  • horny cell
    °¢Áú¼¼Æ÷
  • hybrid cell
    ÀâÁ¾¼¼Æ÷
  • hypersensitized cell
    °ú¹Î°¨¼¼Æ÷
  • immunologically competent cell
    (¢¡immunocyte) ¸é¿ª¼¼Æ÷
  • indeterminate cell
    ºÎÁ¤Çü¼¼Æ÷
  • indifferent cell
    ¹«°ü¼¼Æ÷
  • inducer cell
    À¯µµ¼¼Æ÷
  • inflammatory cell
    ¿°Áõ¼¼Æ÷
  • infundibular cell
    ±ò¶§±â¼¼Æ÷
  • intercalated cell
    »çÀ̼¼Æ÷, °³Àç¼¼Æ÷
  • interdental cell
    û°¢Ä¡¾Æ»çÀ̼¼Æ÷, Ä¡°£¼¼Æ÷
  • interstitial cell
    »çÀÌÁú¼¼Æ÷
  • islet cell
    ¼¶¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • hairy cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´
  • hairy cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´, Åм¼Æ÷¹éÇ÷º´
  • hairy cell leukemia
    Åм¼Æ÷ ¹éÇ÷º´
  • hairy cell leukemia
    ¸ð¹ß»ó¼¼Æ÷ ¹éÇ÷º´
  • hairy-cell leukemia
    ¸ð¹ß»ó¼¼Æ÷¹éÇ÷º´
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷(¡­á¬øà)
  • helmet cell
    Åõ±¸¼¼Æ÷
  • helper T cell
    Á¶·ÂT¼¼Æ÷, º¸Á¶T¼¼Æ÷
  • helper T cell
    º¸Á¶ T¼¼Æ÷
  • helper T cell
    º¸Á¶ T ¼¼Æ÷
  • helper cell
    º¸Á¶¼¼Æ÷
  • helper cell
    Á¶·Â¼¼Æ÷, º¸Á¶¼¼Æ÷
  • helper cell activity
    Á¶·Â¼¼Æ÷´É, º¸Á¶¼¼Æ÷´É
  • hematopoietic cell transplantation
    Á¶Ç÷¼¼Æ÷À̽Ä(¡­á¬øàì¹ãÕ)
  • hematopoietic stem cell
    Á¶Ç÷°£¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç(̴̰?Ë´ËÑËâ).
  • mixed lymphocyte culture
    ¸²ÇÁ±¸È¥ÇÕ¹è¾ç(¡­ûèùêÏ¹ÛÆå×).
  • mixed lymphocyte culture(MLC)
  • mixed lymphocyte reaction
    ¸²ÇÁ±¸ È¥ÇÕ¹è¾ç¹ÝÀÀ
  • mixed lymphocyte response(MLR)
  • mixed melting point
    È¥À¶Á¡(ûèë×ïÇ).
  • mixed mesodermal tumor
    È¥ÇÕ Á߹迱¼º Á¾¾ç
  • mixed mesodermal tumor
    È¥ÇÕ¼º Á߹迱¼º Á¾¾ç(¡­ ñéÛÏç¨àõ ðþåË)
  • mixed mullerian sarcoma
    È¥ÇÕ ¹Á·¯¸®¾È À°Á¾
  • mixed mullerian tumor
    È¥ÇÕ¼º ¹Á·¯ Á¾¾ç, È¥ÇÕ¼º Muller Á¾¾ç(ûèùêàõ ¡­ ðþåË)
  • mixed nerve
    È¥ÇսŰæ(ûèùêãêÌè).
  • mixed nerve
    È¥ÇսŰæ
  • mixed nystagmus
    È¥ÇÕ¾ÈÁø
  • mixed odontoma
    È¥ÇÕ¼º Ä¡¾ÆÁ¾(¡­àõöÍä³ðþ).
  • mixed order reaction
    È¥ÇÕÂ÷¹ÝÀÀ(ûèùêó­ Úãëë).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
ML Licentiate in Medicine; Licentiate in Midwifery; malignant lymphoma; marked latency; maximum likelih...
ML-H malignant lymphoma, histiocytic
ML-PDL malignant lymphoma, poorly differentiated lymphocytic
MTL mantle zone lymphoma
NHML non-Hodgkin malignant lymphoma
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
LC large colony
LGV large granular vesicles
LLC large luteal cells
LS large subunit
L.F.D. large-for-dates
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cornified epithelial cell
    °¢È­ »óÇÇ ¼¼Æ÷
  • cortical cell
    ÇÇÁú ¼¼Æ÷
  • crystal cell
    °áÁ¤ ¼¼Æ÷
    ³»ºÎ¿¡ °¢Á¾ °áÁ¤À» ÇÔÀ¯ÇÏ´Â ¼¼Æ÷. ºÐºñ ¼¼Æ÷ÀÇ ÀÏÁ¾À¸·Î, º¸Åë ÁÖÀ§ÀÇ ¼¼Æ÷¿Í ¸ð¾çÀÌ ¾à°£ ´Ù¸£´Ù. Á¤¹æÁ¤°è ¶Ç´Â ´Ü»çÁ¤°è·Î µÈ Å« ¿Á»ì»ê Ä®½· °áÁ¤À» º£°í´Ï¾Æ¼Ó µî ½Ä¹°Á¶Á÷ ³»¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Ù. ¶§·Î´Â ¼ÒÇüÀÇ °áÁ¤ÀÌ ´Ù¼ö ±ºÁýÇÏ¿© °áÁ¤»ç°¡ µÇ°Å³ª ħ»ó °áÁ¤ÀÌ ´Ù¼ö ÆòÇàÀ¸·Î ¹è¿­µÇ¾î °áÁ¤ ¼ÓÀÌ µÈ´Ù
  • cylindrical cell
    ¿øÁÖÇü ¼¼Æ÷, ¿øÁÖ»ó ¼¼Æ÷
  • daughter cell
    µþ ¼¼Æ÷, ³¶ ¼¼Æ÷
    1. ¸ð¼¼Æ÷°¡ ºÐ¿­ÇÏ¿© »ý±â´Â ¼¼Æ÷. 2. ¼¼Æ÷ ºÐ¿­ÀÇ °á°ú·Î »ý±ä 2°³ÀÇ »õ·Î¿î ¼¼Æ÷. ºÐ¿­ ÀüÀÇ ¸ð¼¼Æ÷¿¡ ´ëÇØ¼­ µþ ¼¼Æ÷¶ó°í ÇÏ¸ç ³¶ ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. µþ ¼¼Æ÷ÀÇ ÇÙÀº 2°³°¡ ¼­·Î ³»¿ëÀÌ °°À¸¸ç, ¶Ç ¸ð¼¼Æ÷ÀÇ ÇÙ°úµµ ¶È°°Àºµ¥ ¼¼Æ÷ÁúÀº ¾à°£ ´Ù¸£´Ù. °¨¼öºÐ¿­ÀÇ Á¦1ºÐ¿­¿¡ ÀÇÇÏ¿© »ý±â´Â 2°³ÀÇ µþ¼¼Æ÷ÀÇ ¿°»öü ¼ö´Â ¸ð¼¼Æ÷ÀÇ ¹Ý¼ö·Î µÇ¾î ÀÖ´Â °ÍÀÌ º¸ÅëÀÌ´Ù.
  • Deiters cell
    ´ÙÀÌÅ׸£½º ¼¼Æ÷
    ³»ÀÌÀÇ ´ÞÆØÀ̰ü ³»ÀÇ ±âÀú¸· À§¿¡ ÀÖ´Â ÄÚ¸£Æ¼±â¸¦ ±¸¼ºÇÏ´Â ÀÏÁ¾ÀÇ ¼¼Æ÷. Á÷Á¢ ¼Ò¸® °¨°¢À» ¹Þ´Â ¿ÜÀ¯¸ð¼¼Æ÷ °£±ØÀ» ä¿ì°í ÀÖ´Â ÁöÁö¼¼Æ÷.
  • delta cell tumor
    µ¨Å¸ ¼¼Æ÷ Á¾¾ç
    ¼Ò¸¶Å佺ŸƾÀ» ºÐºñÇÏ´Â Á¾¾çÀ¸·Î ¼Ò¸¶Å佺ŸƾÁ¾
  • diploid cell
    2¹èü ¼¼Æ÷
    Á¤»óÀÇ 2¹è¼ºÀÇ ¿°»öü, ¶Ç´Â 2°³ÀÇ ÇÙÀ» °¡Áø ¼¼Æ÷. Á¤»óÀÎ Á¶Á÷ ¾È¿¡¼­´Â ¼öÁ¤¶õÀ̳ª ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ º¼ ¼ö ÀÖ´Ù. ÀΰøÀûÀ¸·Î´Â HVJ³ª NDA µîÀÇ ¹ÙÀÌ·¯½º³ª
  • direct cell division
    Á÷Á¢ ¼¼Æ÷ ºÐ¿­
  • disintegrated cell
    ºØ±« ¼¼Æ÷
  • dorsal horn cell
    Èİ¢ ¼¼Æ÷, ¹è°¢ ¼¼Æ÷
  • dorsal horn pain transmission cell
    ¹è°¢ ÅëÁõ Àü´Þ ¼¼Æ÷, ¹è°¢ µ¿Åë Àü´Þ ¼¼Æ÷
  • ductal cell
    µµ°ü ¼¼Æ÷
  • ductule cell
    ¼Ò°ü ¼¼Æ÷
  • ealry squamous cell calcinoma
    ÃÊ±â ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ±¸°­ ³» °¡Àå ÈçÇÑ ¾Ç¼º ÁúȯÀ̰í Ä¡°úÀǻ簡 Ä¡·áÇÏ´Â ¸î ¾È µÇ´Â Ä¡¸íÀû ÁúȯÀÇ ÇϳªÀÌ´Ù. Çǰ³ »óÇÇ ¼¼Æ÷ÀÇ ¾Ç¼º ¾ÏÁ¾¼º Áõ½ÄÀÌ´Ù. ¹é¹ÝÁõÀ̶ó°í ÇÏ´Â ÀÓ»ó ¿ë¾î·Îµµ ºÒ¸®´Â ¼Ò»ó »óÇÇ ºñÈÄ¿Í µ¿ÀÏÇÑ º´¼Ò¸¦ º¸¿©ÁØ´Ù. °¡Àå ÈçÇÑ ¿øÀÎÀ¸·Î »ý°¢µÇ´Â °ÍÀº ½À°üÀûÀÎ Èí¿¬°ú ¾ËÄÝÀÌ´Ù. ±¸°­ Á¡¸·¿¡ ¼Ò»ó ¹é»ö ¹ÝÁ¡À» ¸¸µå´Âµ¥ ÀÌ´Â »ý¸®Àû °ú°¢È­¿Í ºñ½ÁÇÏ°Ô º¸ÀδÙ. º´¼Ò¸¦ °ÇÁ¶½ÃŲ ÈÄ ÀÚ¼¼È÷ °üÂûÇϸé ÀÌÇü¼º º´¼ÒÀÇ Ç¥¸éÀÌ ÀϹÝÀûÀ¸·Î ´õ °ÅÄ¥°í ÂÞ±ÛÂÞ±ÛÇÑ °ÍÀ» º¼ ¼ö ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
carbohydrates and hypoglycaemic agents A collective term for carbohydrates and agents used to lower the level of glucose in the blood.
(12 Dec 1998)
carboxyl and carbamoyl transferases <enzyme> A group of enzymes that catalyze the transfer of carboxyl- or carbamoyl- groups.
Registry number: EC 2.1.3
(12 Dec 1998)
Gaddum and Schild test A sensitive method for identification of epinephrine in tissue or other material, based on the fluorescence of epinephrine exposed to ultraviolet light in the presence of alkali and oxygen; sensitivity ranges from 1:50 to 1:100 million.
(05 Mar 2000)
vaginal creams, foams and jellies Medicated dosage forms for topical application in the vagina. A cream is a semisolid emulsion containing suspended or dissolved medication; a foam is a dispersion of a gas in a medicated liquid resulting in a light, frothy mass; a jelly is a colloidal semisolid mass of a water soluble medicated material, usually translucent. The concept includes vaginal creams, foams, and jellies in general or for which there is no other specific heading.
(12 Dec 1998)
magnesia and alumina oral suspension A mixture of magnesium hydroxide and variable amounts of aluminum oxide; used as an antacid.
(05 Mar 2000)
maintenance and engineering, hospital Hospital department whose primary function is the upkeep and supervision of the buildings and grounds and the maintenance of hospital physical plant and equipment which requires engineering expertise.
(12 Dec 1998)
P and P test A test formerly used by some to control anticoagulant therapy with bishydroxycoumarin and indandione drugs.
Synonym: P and P test.
(05 Mar 2000)
malignancy and immunodeficiency <radiology> High risk of malignancy (especially lymphoma/leukaemia, GI tumours): X-linked agammaglobulinaemia (Bruton's), common variable immunodeficiency, severe combined immunodeficiency (SCID kids), ataxia-telangectasia, Wiscott-Aldrich syndrome, selective IgA deficiency
(12 Dec 1998)
Papillon-Leage and Psaume syndrome <syndrome> An inherited syndrome, lethal in males, with varying combinations of defects of the oral cavity, face, and hands, including lobulated or bifid tongue, cleft or pseudocleft palate, tongue tumours, missing or malpositioned teeth, hypoplastic nasal alar cartilage, depressed nasal bridge, brachydactyly, clinodactyly, incomplete syndactyly, and, frequently, mental retardation.
There are two subtypes recognised. Type I (papillon-leage and psaume syndrome, gorlin-psaume syndrome) is inherited as an x-linked dominant trait and is found only in females and XXY males. Type II (mohr syndrome) is inherited as an autosomal recessive trait.
Inheritance: autosomal recessive and X-linked.
Synonym: OFD syndrome, orofaciodigital syndrome, Papillon-Leage and Psaume syndrome.
(05 Mar 2000)
Gell and Coombs Classification A classification system that differentiates the 4 types of hypersensitivity reactions: Type I: anaphylactic reactions, Type II: cytotoxic reactions, Type III: immune complex reactions, and Type IV: cell-mediated reactions.
(05 Mar 2000)
rate setting and review A method of examining and setting levels of payments.
(12 Dec 1998)
ratio of decayed and filled surfaces An index of decayed and filled permanent surfaces per person, per full complement of 122 tooth surfaces.
(05 Mar 2000)
ratio of decayed and filled teeth An index of decayed and filled permanent teeth per person, per full complement of 28 teeth.
(05 Mar 2000)
receptors, cytoplasmic and nuclear Proteins in the cytoplasm or nucleus that specifically bind signalling molecules and trigger changes which influence the behaviour of cells. The major groups are the steroid hormone receptors, which usually are found in the cytoplasm, and the thyroid hormone receptors, which usually are found in the nucleus. Receptors, unlike enzymes, generally do not catalyze chemical changes in their ligands.
(12 Dec 1998)
maternal age 35 and over Pregnancy in women 35 or more years of age. It is used for normal pregnancies and for problems of pregnancy occurring in a woman's late reproductive years. These include effects on the mother's physical and mental health as well as risks of perinatal mortality and foetal abnormality.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á